AMA002 is a reverse vaccine for the treatment of Diabetes Mellitus type 1 (DM1). DM1 is an autoimmune disease where self-reactive T lymphocytes selectively attack and destroy insulin-producing β cells lodged within the pancreas, leaving the patient unable to secrete insulin and thus maintaining glucose homeostasis. Proinsulin (PI) is considered to be the main primary self-antigen involved in the autoimmune β cell destruction. To date, DM1 cannot be cured and the glucose homeostasis can be more or less maintained in patients by daily insulin injections. Although DM1 is considered to be a manageable disease nowadays, secondary complications of the current therapy are considerable and lead to significant morbidity and mortality. Using AMA002 we intent to restore the immune tolerance to proinsulin and thereby cure the patient from the disease. Experiments have shown that SVac-mediated expression of proinsulin in a mouse model of human DM1 protects the reverse vaccinated animals from developing the disease.